Sign In
Buy R
$264.96
+4.58 (+1.76%)
At Close: Jun 04, 2026
Ryder Third Quarter 2024 Earnings Conference Call Scheduled for October 24, 2024
06:55am, Tuesday, 24'th Sep 2024
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R), a leader in supply chain, dedicated transportation, and fleet management solutions, today provided details regarding its confer
Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System
07:00am, Monday, 23'rd Sep 2024
New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine Procedures BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT)
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
09:45am, Friday, 20'th Sep 2024
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufact
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
06:50am, Friday, 20'th Sep 2024
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl t
Theralase(R) Extends Warrants
05:05pm, Thursday, 19'th Sep 2024
TORONTO, ON / ACCESSWIRE / September 19, 2024 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus
06:00am, Wednesday, 18'th Sep 2024
New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics BELGRADE, MT / ACCESSWIRE / September 18, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medic
NEW YORK, NY / ACCESSWIRE / September 10, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE: R). The
Levi & Korsinsky, LLP Announces $45,000,000 Recovery for Ryder System, Inc. (R). File Your Claim Before Deadline
01:30pm, Tuesday, 17'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE: R). The s
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution
08:30am, Tuesday, 17'th Sep 2024
BOULDER, CO / ACCESSWIRE / September 17, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlo
2 Dividend-Paying Transport Equipment & Leasing Stocks to Watch
02:55pm, Monday, 16'th Sep 2024
Here we pick two stocks, Ryder (R) and Greenbrier (GBX) from the Transportation - Equipment and Leasing industry, with a solid five-year dividend growth history.
Ryder System: Don't Underestimate Its Shift To Leasing
04:50am, Saturday, 14'th Sep 2024
Ryder System shares have gained 40% over the past year, outperforming the S&P 500, but are down 6% from their high. Management's conservative accounting and shift towards long-term leases have de-risk
Ryder Stock Rallies 20% in 6 Months: What Should Investors Do Now?
02:10pm, Friday, 13'th Sep 2024
With R shares appreciating this year, we assess the current positioning of the stock to determine if it's a good investment choice at this juncture.
Tenon(R) Medical Announces the Introduction of the Catamaran(R) SE SI Joint Fusion System
08:56pm, Thursday, 12'th Sep 2024
~ New SI Joint Fixation Device Offers a 30% Reduction in Implant Size Providing Physicians Choices for Varying Anatomy and Treatment Strategies with the Catamaran Technology ~ ~ The SE System Can Also
First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024 Clinical supply agreement for acalabrutinib with AstraZeneca in place
Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NAS
